GERN vs. RMD

Last updated Jun 3, 2026

GERN (Geron Corporation) and RMD (ResMed Inc.) are both stocks. Both are in the Healthcare sector — GERN in Biotechnology, RMD in Medical Instruments & Supplies. Over the past 10 years, GERN returned -8.86%/yr vs 13.14%/yr for RMD. At a 0.23 correlation, their price movements are largely independent.

Performance

GERN vs. RMD - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Geron Corporation (GERN) and ResMed Inc. (RMD). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, GERN achieves a -11.36% return, which is significantly higher than RMD's -23.70% return. Over the past 10 years, GERN has underperformed RMD with an annualized return of -8.86%, while RMD has yielded a comparatively higher 13.14% annualized return.

GERN

• 1D: -3.31%
• 1M: -25.95%
• YTD: -11.36%
• 6M: -4.88%
• 1Y: -18.18%
• 3Y*: -31.25%
• 5Y*: -3.53%
• 10Y*: -8.86%

RMD

• 1D: -1.94%
• 1M: -10.56%
• YTD: -23.70%
• 6M: -26.73%
• 1Y: -24.35%
• 3Y*: -5.15%
• 5Y*: -1.30%
• 10Y*: 13.14%

*Multi-year figures are annualized to reflect compound growth (CAGR)

GERN vs. RMD - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
GERN Geron Corporation	-11.36%	-62.71%	67.77%	-12.81%	98.36%	-23.27%	16.91%	36.00%	-44.44%	-13.04%
RMD ResMed Inc.	-23.70%	6.26%	34.18%	-16.55%	-19.47%	23.41%	38.33%	37.85%	36.38%	39.06%

Correlation

The correlation between GERN and RMD is 0.18, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.18
Correlation (3Y) Calculated over the trailing 3-year period	0.18
Correlation (5Y) Calculated over the trailing 5-year period	0.21
Correlation (10Y) Calculated over the trailing 10-year period	0.23
Correlation (All Time) Calculated using the full available price history since Aug 1, 1996	0.23

Fundamentals

EPS GERN : -$0.10 RMD : $13.78
PS Ratio GERN : 3.98 RMD : 3.64
Total Revenue (TTM) GERN : $196.12M RMD : $5.54B
Gross Profit (TTM) GERN : $119.67M RMD : $3.42B
EBITDA (TTM) GERN : -$40.62M RMD : $2.10B

Return for Risk

GERN vs. RMD — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GERN

GERN Risk / Return Rank: 24
GERN Sharpe Ratio Rank: 28
GERN Sortino Ratio Rank: 29
GERN Omega Ratio Rank: 30
GERN Calmar Ratio Rank: 19
GERN Martin Ratio Rank: 15

RMD

RMD Risk / Return Rank: 7
RMD Sharpe Ratio Rank: 4
RMD Sortino Ratio Rank: 6
RMD Omega Ratio Rank: 8
RMD Calmar Ratio Rank: 16
RMD Martin Ratio Rank: 3

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GERN vs. RMD - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Geron Corporation (GERN) and ResMed Inc. (RMD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	GERN	RMD	Difference
Sharpe ratio Return per unit of total volatility	-0.29	-1.04	+0.75
Sortino ratio Return per unit of downside risk	-0.00	-1.37	+1.37
Omega ratio Gain probability vs. loss probability	1.00	0.83	+0.17
Calmar ratio Return relative to maximum drawdown	-0.58	-0.66	+0.08
Martin ratio Return relative to average drawdown	-1.14	-1.60	+0.46
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

GERN vs. RMD - Sharpe Ratio Comparison

The current GERN Sharpe Ratio is -0.29, which is higher than the RMD Sharpe Ratio of -1.04. The chart below compares the historical Sharpe Ratios of GERN and RMD, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	GERN	RMD	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.29	-1.04	+0.75
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.04	-0.04	0.00
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.11	0.42	-0.53
Sharpe Ratio (All Time) Calculated using the full available price history	-0.07	0.51	-0.58

Drawdowns

GERN vs. RMD - Drawdown Comparison

The maximum GERN drawdown since its inception was -98.73%, which is greater than RMD's maximum drawdown of -61.61%. Use the drawdown chart below to compare losses from any high point for GERN and RMD.

Drawdown Indicators

	GERN	RMD	Difference
Max Drawdown Largest peak-to-trough decline	-98.73%	-61.61%	-37.12%
Max Drawdown (1Y) Largest decline over 1 year	-40.00%	-37.28%	-2.72%
Max Drawdown (3Y) Largest decline over 3 years	-78.98%	-40.09%	-38.89%
Max Drawdown (5Y) Largest decline over 5 years	-78.98%	-53.99%	-24.99%
Max Drawdown (10Y) Largest decline over 10 years	-86.09%	-53.99%	-32.10%
Current Drawdown Current decline from peak	-98.32%	-37.28%	-61.04%
Average Drawdown Average peak-to-trough decline	-86.15%	-15.97%	-70.18%
Ulcer Index Depth and duration of drawdowns from previous peaks	20.14%	15.37%	+4.77%

Volatility

GERN vs. RMD - Volatility Comparison

Geron Corporation (GERN) has a higher volatility of 15.10% compared to ResMed Inc. (RMD) at 9.37%. This indicates that GERN's price experiences larger fluctuations and is considered to be riskier than RMD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	GERN	RMD	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.10%	9.37%	+5.73%
Volatility (6M) Calculated over the trailing 6-month period	46.90%	19.04%	+27.86%
Volatility (1Y) Calculated over the trailing 1-year period	64.01%	23.47%	+40.54%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	82.39%	31.04%	+51.35%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	78.09%	31.51%	+46.58%

Dividends

GERN vs. RMD - Dividend Comparison

GERN has not paid dividends to shareholders, while RMD's dividend yield for the trailing twelve months is around 1.31%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
GERN Geron Corporation	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
RMD ResMed Inc.	1.31%	0.94%	0.88%	1.07%	0.83%	0.62%	0.73%	0.98%	1.26%	1.61%	2.03%	2.16%

Financials

GERN vs. RMD - Profitability Comparison

The chart below illustrates the profitability comparison between Geron Corporation and ResMed Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

GERN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Geron Corporation reported a gross profit of 0.00 and revenue of 51.84M. Therefore, the gross margin over that period was 0.0%.

RMD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, ResMed Inc. reported a gross profit of 890.98M and revenue of 1.43B. Therefore, the gross margin over that period was 62.3%.

GERN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Geron Corporation reported an operating income of 158.00K and revenue of 51.84M, resulting in an operating margin of 0.3%.

RMD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, ResMed Inc. reported an operating income of 499.81M and revenue of 1.43B, resulting in an operating margin of 34.9%.

GERN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Geron Corporation reported a net income of -3.64M and revenue of 51.84M, resulting in a net margin of -7.0%.

RMD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, ResMed Inc. reported a net income of 398.73M and revenue of 1.43B, resulting in a net margin of 27.9%.

Frequently Asked Questions

Can I hold both GERN and RMD in my portfolio?

GERN and RMD have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, GERN or RMD?

GERN has higher volatility (15.10%) compared to RMD (9.37%). In terms of maximum drawdown, GERN dropped -98.73% vs RMD's -61.61%.

Which has better risk-adjusted returns?

GERN currently has the higher Sharpe Ratio (-0.29 vs -1.04), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.